Acute Pain Therapeutics Market is Forecast to Show Low Growth until 2017
Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Acute Pain Therapeutics Market is Forecast to Show Low Growth until 2017 GlobalData estimates that the global acute pain therapeutics market was valued at $10.3 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.7% over the next seven years, to reach $14.2 billion by 2017. This slow growth is primarily attributed to a low treatment seeking behavior, disease awareness and usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs. Need for First-in-Class Drugs GlobalData’s research indicates that the acute pain pipeline is weak with molecules in various phases of clinical development. The first-in-class molecules seem to have distinct advantages over the current products in terms of better disease management. Although the unmet need of the acute pain market is low and the treatment relies on older therapies and drugs, the market needs novel therapies offering better results in terms of safety and efficacy. Changing Future Landscape of the Acute Pain Market AcelRX Pharmaceuticals, Inc., Acura Pharmaceuticals, Inc /King Pharmaceuticals, Cara Therapeutics, GlaxosmithKline, Grunenthal GMBH, QRX Pharma, Transdel Pharmaceuticals, Inc. and Xenome Ltd. are going to be the
key players in future. GlobalData has profiles of all these companies as they hold important pipeline drugs in late stage development for acute pain. The existing market landscape remains competitive, because the treatment of acute pain relies on established, older therapies like non-steroidal anti-inflammatory drugs (NSAIDS), opioids, and Cyclooxygenase-II (COX-II) inhibitors. The market scenario will change after the launch of new disease modifying therapies such as T-type calcium channel blocker, imidazoline I2 binding receptor, ligand activated therapy, platelet glycoprotein IIb/IIIa receptor, conopeptide analog, and transient receptor potential vanilloid-1 (TRPV1) antagonist. Weak Pipeline is Likely to Result in Slow Growth for the Acute Pain Market GlobalData analysis shows that the acute pain therapeutics pipeline is weak, with 21 molecules in various phases of clinical development, including six first-in-class molecules. These first-in-class molecules are in the early stage of clinical development, so their impact on the market will be on the later stage. In the case of acute pain therapeutics, most of the late stage pipeline does not have a novel mechanism of action. Thus the pipeline for the acute pain therapeutics market is weak.
For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Pain-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare Visit our report store: http://www.globaldata.com For more details contact: email@example.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782